Cartesian Therapeutics(US:RNAC) Newsfilterยท2024-06-06 11:05Core Insights - Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases [4] - The company has granted an inducement award to a new employee, consisting of an option to purchase 11,000 shares at an exercise price of $36.00 [1] - The option vests 25% on June 3, 2025, with the remainder vesting in three equal annual installments, fully vesting by June 3, 2028 [1] Company Overview - Cartesian Therapeutics is developing its lead asset, Descartes-08, which is in Phase 2b clinical development for generalized myasthenia gravis [4] - The company plans additional Phase 2 studies in systemic lupus erythematosus and basket trials for other autoimmune indications [4] - The clinical pipeline also includes Descartes-15, a next-generation autologous anti-BCMA mRNA CAR-T [4]